301 related articles for article (PubMed ID: 26005917)
1. Anti-cancer chalcones: Structural and molecular target perspectives.
Mahapatra DK; Bharti SK; Asati V
Eur J Med Chem; 2015 Jun; 98():69-114. PubMed ID: 26005917
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective.
Kumar V; Dhawan S; Girase PS; Awolade P; Shinde SR; Karpoormath R; Singh P
Curr Med Chem; 2021 Oct; 28(33):6805-6845. PubMed ID: 33749549
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Potential of Naringenin, Biosynthesis, Molecular Target, and Structural Perspectives.
Prakash O; Singh R; Singh N; Usmani S; Arif M; Kumar R; Ved A
Mini Rev Med Chem; 2022; 22(5):758-769. PubMed ID: 34517796
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of chalcones as cardiovascular agents.
Mahapatra DK; Bharti SK
Life Sci; 2016 Mar; 148():154-72. PubMed ID: 26876916
[TBL] [Abstract][Full Text] [Related]
5. Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications.
Mahapatra DK; Bharti SK; Asati V; Singh SK
Eur J Med Chem; 2019 Jul; 174():142-158. PubMed ID: 31035237
[TBL] [Abstract][Full Text] [Related]
6. Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.
Mahapatra DK; Bharti SK; Asati V
Eur J Med Chem; 2015 Aug; 101():496-524. PubMed ID: 26188621
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents.
Reddy MV; Su CR; Chiou WF; Liu YN; Chen RY; Bastow KF; Lee KH; Wu TS
Bioorg Med Chem; 2008 Aug; 16(15):7358-70. PubMed ID: 18602831
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities.
Srinivasan B; Johnson TE; Lad R; Xing C
J Med Chem; 2009 Nov; 52(22):7228-35. PubMed ID: 19883086
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
Kumar D; Kumar NM; Akamatsu K; Kusaka E; Harada H; Ito T
Bioorg Med Chem Lett; 2010 Jul; 20(13):3916-9. PubMed ID: 20627724
[TBL] [Abstract][Full Text] [Related]
10. Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives.
Mahapatra DK; Asati V; Bharti SK
Eur J Med Chem; 2015 Mar; 92():839-65. PubMed ID: 25638569
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones.
Cagir A; Odaci B; Varol M; Akcok I; Okur O; Koparal AT
Anticancer Agents Med Chem; 2018 Feb; 17(14):1915-1923. PubMed ID: 28554313
[TBL] [Abstract][Full Text] [Related]
12. Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents.
Kim SH; Lee E; Baek KH; Kwon HB; Woo H; Lee ES; Kwon Y; Na Y
Bioorg Med Chem Lett; 2013 Jun; 23(11):3320-4. PubMed ID: 23608763
[TBL] [Abstract][Full Text] [Related]
13. Chalcones incorporated pyrazole ring inhibit proliferation, cell cycle progression, angiogenesis and induce apoptosis of MCF7 cell line.
Mohamed MF; Mohamed MS; Fathi MM; Shouman SA; Abdelhamid IA
Anticancer Agents Med Chem; 2014; 14(9):1282-92. PubMed ID: 25323033
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel β-carboline based chalcones with high cytotoxic activity against breast cancer cells.
Chauhan SS; Singh AK; Meena S; Lohani M; Singh A; Arya RK; Cheruvu SH; Sarkar J; Gayen JR; Datta D; Chauhan PM
Bioorg Med Chem Lett; 2014 Jul; 24(13):2820-4. PubMed ID: 24844196
[TBL] [Abstract][Full Text] [Related]
15. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.
Mai CW; Yaeghoobi M; Abd-Rahman N; Kang YB; Pichika MR
Eur J Med Chem; 2014 Apr; 77():378-87. PubMed ID: 24675137
[TBL] [Abstract][Full Text] [Related]
16. Brine shrimp lethality assay 'an effective prescreen': microwave-assisted synthesis, BSL toxicity and 3DQSAR studies-based designing, docking and antitumor evaluation of potent chalcones.
Nazir S; Ansari FL; Hussain T; Mazhar K; Muazzam AG; Qasmi ZU; Makhmoor T; Noureen H; Mirza B
Pharm Biol; 2013 Sep; 51(9):1091-103. PubMed ID: 23745524
[TBL] [Abstract][Full Text] [Related]
17. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
Boumendjel A; Boccard J; Carrupt PA; Nicolle E; Blanc M; Geze A; Choisnard L; Wouessidjewe D; Matera EL; Dumontet C
J Med Chem; 2008 Apr; 51(7):2307-10. PubMed ID: 18293907
[TBL] [Abstract][Full Text] [Related]
18. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFα-induced nuclear factor-κB activation inhibition.
Zuo Y; Yu Y; Wang S; Shao W; Zhou B; Lin L; Luo Z; Huang R; Du J; Bu X
Eur J Med Chem; 2012 Apr; 50():393-404. PubMed ID: 22386368
[TBL] [Abstract][Full Text] [Related]
20. Replacement of the double bond of antitubulin chalcones with triazoles and tetrazoles: Synthesis and biological evaluation.
Mesenzani O; Massarotti A; Giustiniano M; Pirali T; Bevilacqua V; Caldarelli A; Canonico P; Sorba G; Novellino E; Genazzani AA; Tron GC
Bioorg Med Chem Lett; 2011 Jan; 21(2):764-8. PubMed ID: 21167709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
